Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006
Authors' objectives
To summarise the currently available evidence on satraplatin for second-line hormone-refractory prostate cancer.
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk